chloroquine and derivatives - for COVID 19 outpatients   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.08 [0.15, 7.72]< 10%3 studies (3/-)46.8 %some concernnot evaluable moderatecrucial-
clinical improvement 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
hospitalization 0.79 [0.42, 1.48]< 10%2 studies (2/-)77.0 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

adverse events 2.74 [1.80, 4.18]< 10%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 97 97